1. Cutaneous S100-negative, CD1a-positive histiocytosis successfully treated with combination therapy of oral methotrexate and corticosteroid
- Author
-
Hajime Iizuka, Yasushi Ohishi, Hidetsugu Sato, Akemi Ishida-Yamamoto, Chiaki Takahashi, Wakana Nomura, Masaru Honma, Jiro Uehara, Kazuhiro Kaneta, and Akiyoshi Takagi
- Subjects
Adult ,Male ,Pathology ,medicine.medical_specialty ,Combination therapy ,medicine.drug_class ,Birbeck granules ,Prednisolone ,Dermatology ,Ultraviolet therapy ,Antigens, CD1 ,medicine ,Humans ,Glucocorticoids ,Histiocyte ,integumentary system ,business.industry ,S100 Proteins ,General Medicine ,medicine.disease ,Histiocytosis ,Methotrexate ,Corticosteroid ,Drug Therapy, Combination ,Dermatologic Agents ,business ,medicine.drug - Abstract
S100-negative, CD1a-positive histiocytosis is a rare histiocytic disorder characterized by proliferation of histiocytic cells possessing a phenotype of epidermal Langerhans cells except for the lack of S100 expression and Birbeck granules. We report the case of a Japanese man suffering from S100-negative, CD1a-positive histiocytosis. The patient showed numerous smooth erythematous 5-10-mm papules/nodules on most of his body. The key histopathological feature was the presence of dermal infiltrates of non-epidermotropic S100-negative CD1a-positive mononuclear cells. No systemic involvement was detected. Initially bath-psoralen plus ultraviolet A therapy was effective, but the lesions became recalcitrant to this treatment. Methylprednisolone pulse therapy followed by low-dose methotrexate (up to 30 mg/week) in combination with prednisolone (15 mg/day) effectively controlled the skin lesions.
- Published
- 2015